About this Research Topic
The current diabetes treatment strategy is a holistic approach to the patient, aiming beyond glycemic control to reduce the overall risk and improvements in several biomarkers. From a historical perspective, the treatment of diabetes passed through three approaches. Firstly, in the early stages of diabetes treatment, the lower, the better paradigm was guiding the diabetes management, which meant that as lower as possible glycemia values and HbA1c were aimed. In the early 1990s, hypoglycemias’ important negative impact on the patient's outcomes was observed, leading to the lower, the better, without hypoglycemias treatment paradigm. The nowadays paradigm of diabetes management came as a consequence of several observations that pointed out that the diabetes treatment of choice has multiple influences on the overall patient's prognosis, risk, and several biomarkers associated with meaningful outcomes.
Thus, data from cardiovascular outcome trials showed that there are drugs, designed initially to manage hyperglycemia, reducing the cardiovascular risk of the patients with diabetes by decreasing the risk of cardiovascular death, non-fatal myocardial infarction, stroke, or heart failure. Simultaneously, a similar risk reduction regarding renal outcomes was observed, which appears to be consistent with representatives of one class of antidiabetic therapies.
Besides these intrinsic risk reductions (cardiovascular and renal), of paramount importance for the patient with diabetes, the observations from studies organized during the last two decades demonstrated that some diabetes therapies are associated with an impact on several biomarkers of paramount importance as well as with possible long-term impact on the patient's overall risk, especially in this group of patients, like body weight, blood pressure or lipid profile.
This collection will highlight research expertise in the impact of diabetes therapies on other parameters than glycemic control.
Original research, perspectives, and reviews are welcomed. Subtopics may include but are not limited to the impact on diabetes therapies on:
• Cardiovascular and renal risk
• Blood pressure
• Lipid profile
• The risk of microvascular complications
• The risk and progression of diabetic neuropathy
• Patient's reported quality of life
• Inflammation profile
• Insulin sensitivity
Keywords: Diabetes therapies, cardiovascular risk, renal risk, diabetes biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.